Impact of uremic environment on peritoneum: A proteomic view

Journal of Proteomics

Volumn 75, Issue 7, 2012, Pages 2053-2063

  Wang, Hsien Yi ^a,b   Lin, Ching Yih ^a   Chien, Chih Chiang ^a,c   Kan, Wei Chih ^a,c   Tian, Yu Feng ^a,b   Liao, Pao Chi ^d   Wu, Hsin Yi ^e   Su, Shih Bin ^a,f  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^c CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e INSTITUTE OF CHEMISTRY   (Taiwan)

^f SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

2 DE; Mass spectrometry; Peritoneal fluid; Uremia

Indexed keywords

ACTIN; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; APOPTOSIS INHIBITOR; APOPTOSIS INHIBITOR 2; GLIAL FIBRILLARY ACIDIC PROTEIN; KININOGEN; KININOGEN I; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CHOLECYSTECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MALE; MEMBRANE PERMEABILITY; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SYNAPSE VESICLE; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UREMIA; WESTERN BLOTTING;

ASCITIC FLUID; BIOLOGICAL MARKERS; FEMALE; GALLSTONES; HUMANS; MALE; PERITONEAL DIALYSIS; PROTEOME; PROTEOMICS; UREMIA;

EID: 84862826334     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.01.011     Document Type: Article

References (67)

1. Miyata T., Maeda K., Kurokawa K., van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997, 12:255-258.
2. Miyata T., van Ypersele de Strihou C., Kurokawa K., Baynes J.W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999, 55:389-399.
3. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
4. Wieslander A., Linden T., Musi B., Jarkelid L., Speidel R., Beck W., et al. Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids. Contrib Nephrol 2001, 82-89.
5. Hoff C.M. Experimental animal models of encapsulating peritoneal sclerosis. Perit Dial Int 2005, 25(Suppl 4):S57-S66.
6. Williams J.D., Craig K.J., Topley N., Von Ruhland C., Fallon M., Newman G.R., et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002, 13:470-479.
7. Sherif A.M., Nakayama M., Maruyama Y., Yoshida H., Yamamoto H., Yokoyama K., et al. Quantitative assessment of the peritoneal vessel density and vasculopathy in CAPD patients. Nephrol Dial Transplant 2006, 21:1675-1681.
8. Honda K., Hamada C., Nakayama M., Miyazaki M., Sherif A.M., Harada T., et al. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008, 3:720-728.
9. Muchaneta-Kubara E.C., Sayed-Ahmed N., el Nahas A.M. Subtotal nephrectomy: a mosaic of growth factors. Nephrol Dial Transplant 1995, 10:320-327.
10. Amann K., Kronenberg G., Gehlen F., Wessels S., Orth S., Munter K., et al. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 1998, 13:1958-1966.
11. Combet S., Ferrier M.L., Van Landschoot M., Stoenoiu M., Moulin P., Miyata T., et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 2001, 12:2146-2157.
12. Maurer M.H. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF). Mass Spectrom Rev 2010, 29:17-28.
13. Liu Y.W., Yang M.H., Liu P.Y., Lee C.H., Liao P.C., Tyan Y.C. Proteomic analysis of pericardial effusion: Characteristics of tuberculosis-related proteins. Proteomics Clin Appl 2008, 2:458-466.
14. Tyan Y.C., Wu H.Y., Su W.C., Chen P.W., Liao P.C. Proteomic analysis of human pleural effusion. Proteomics 2005, 5:1062-1074.
15. Tyan Y.C., Wu H.Y., Lai W.W., Su W.C., Liao P.C. Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry. J Proteome Res 2005, 4:1274-1286.
16. Tan L.B., Chen K.T., Tyan Y.C., Liao P.C., Guo H.R. Proteomic analysis for human urinary proteins associated with arsenic intoxication. Proteomics Clin Appl 2008, 2:1087-1098.
17. Bennett M.R., Ravipati N., Ross G., Nguyen M.T., Hirsch R., Beekman R.H., et al. Using proteomics to identify preprocedural risk factors for contrast induced nephropathy. Proteomics Clin Appl 2008, 2:1058-1064.
18. Tyan Y.C., Guo H.R., Liu C.Y., Liao P.C. Proteomic profiling of human urinary proteome using nano-high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Chim Acta 2006, 579:158-176.
19. Raaijmakers R., Pluk W., Schroder C.H., Gloerich J., Cornelissen E.A., Wessels H.J., et al. Proteomic profiling and identification in peritoneal fluid of children treated by peritoneal dialysis. Nephrol Dial Transplant 2008, 23:2402-2405.
20. Tyan Y.C., Liao P.C. Proteomics analysis of serous fluids and effusions: pleural, pericardial, and peritoneal. Proteomics Clin Appl 2007, 1:834-844.
21. Sritippayawan S., Chiangjong W., Semangoen T., Aiyasanon N., Jaetanawanitch P., Sinchaikul S., et al. Proteomic analysis of peritoneal dialysate fluid in patients with different types of peritoneal membranes. J Proteome Res 2007, 6:4356-4362.
22. Ferrero S., Gillott D.J., Anserini P., Remorgida V., Price K.M., Ragni N., et al. Vitamin D binding protein in endometriosis. J Soc Gynecol Investig 2005, 12:272-277.
23. Ferrero S., Gillott D.J., Remorgida V., Anserini P., Leung K.Y., Ragni N., et al. Proteomic analysis of peritoneal fluid in women with endometriosis. J Proteome Res 2007, 6:3402-3411.
24. Ferrero S., Gillott D.J., Remorgida V., Anserini P., Ragni N., Grudzinskas J.G. Peritoneal fluid proteome in women with different ASRM stages of endometriosis. Gynecol Endocrinol 2008, 24:433-441.
25. Ferrero S., Gillott D.J., Remorgida V., Anserini P., Ragni N., Grudzinskas J.G. Proteomic analysis of peritoneal fluid in fertile and infertile women with endometriosis. J Reprod Med 2009, 54:32-40.
26. Ferrero S., Gillott D.J., Remorgida V., Anserini P., Ragni N., Grudzinskas J.G. GnRH analogue remarkably down-regulates inflammatory proteins in peritoneal fluid proteome of women with endometriosis. J Reprod Med 2009, 54:223-231.
27. Wolfler M.M., Meinhold-Heerlein I.M., Sohngen L., Rath W., Knuchel R., Neulen J., et al. Two-dimensional gel electrophoresis in peritoneal fluid samples identifies differential protein regulation in patients suffering from peritoneal or ovarian endometriosis. Fertil Steril 2011, 95:2764-2768.
28. Amon L.M., Law W., Fitzgibbon M.P., Gross J.A., O'Briant K., Peterson A., et al. Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One 2010, 5:e11137.
29. Honore B., Vorum H., Knudsen A. Proteomic profiling of peritoneal rinse fluid sediment separates patients with ovarian cancer from women admitted for cesarean section. A pilot study. Scand J Clin Lab Invest 2010, 70:470-477.
30. Mercolino T.J., Arnold L.W., Hawkins L.A., Haughton G. Normal mouse peritoneum contains a large population of Ly-1+ (CD5) B cells that recognize phosphatidyl choline. Relationship to cells that secrete hemolytic antibody specific for autologous erythrocytes. J Exp Med 1988, 168:687-698.
31. Birkhofer A., Rehbock J., Fricke H. T lymphocytes from the normal human peritoneum contain high frequencies of Th2-type CD8+ T cells. Eur J Immunol 1996, 26:957-960.
32. Homsi E., Janino P., de Faria J.B. Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure. Kidney Int 2006, 69:1385-1392.
33. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997, 16:6914-6925.
34. Li X., Yang Y., Ashwell J.D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature 2002, 416:345-347.
35. Uren A.G., Pakusch M., Hawkins C.J., Puls K.L., Vaux D.L. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors. Proc Natl Acad Sci U S A 1996, 93:4974-4978.
36. Yoneda T., Imaizumi K., Maeda M., Yui D., Manabe T., Katayama T., et al. Regulatory mechanisms of TRAF2-mediated signal transduction by Bcl10, a MALT lymphoma-associated protein. J Biol Chem 2000, 275:11114-11120.
37. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008, 30:689-700.
38. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998, 17:2215-2223.
39. Mace P.D., Linke K., Feltham R., Schumacher F.R., Smith C.A., Vaux D.L., et al. Structures of the cIAP2 RING domain reveal conformational changes associated with ubiquitin-conjugating enzyme (E2) recruitment. J Biol Chem 2008, 283:31633-31640.
40. Petersen S.L., Wang L., Yalcin-Chin A., Li L., Peyton M., Minna J., et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12:445-456.
41. Varfolomeev E., Blankenship J.W., Wayson S.M., Fedorova A.V., Kayagaki N., Garg P., et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 2007, 131:669-681.
42. Gaither A., Porter D., Yao Y., Borawski J., Yang G., Donovan J., et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007, 67:11493-11498.
43. Tamm I., Kornblau S.M., Segall H., Krajewski S., Welsh K., Kitada S., et al. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin Cancer Res 2000, 6:1796-1803.
44. Nemoto T., Kitagawa M., Hasegawa M., Ikeda S., Akashi T., Takizawa T., et al. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 2004, 76:253-259.
45. Hasegawa T., Suzuki K., Sakamoto C., Ohta K., Nishiki S., Hino M., et al. Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 2003, 101:1164-1171.
46. Kempkensteffen C., Hinz S., Christoph F., Krause H., Koellermann J., Magheli A., et al. Expression of the apoptosis inhibitor livin in renal cell carcinomas: correlations with pathology and outcome. Tumour Biol 2007, 28:132-138.
47. Akyurek N., Ren Y., Rassidakis G.Z., Schlette E.J., Medeiros L.J. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer 2006, 107:1844-1851.
48. Esposito I., Kleeff J., Abiatari I., Shi X., Giese N., Bergmann F., et al. Overexpression of cellular inhibitor of apoptosis protein 2 is an early event in the progression of pancreatic cancer. J Clin Pathol 2007, 60:885-895.
49. Akalal D.B., Nagle G.T. Mollusk-derived growth factor: cloning and developmental expression in the central nervous system and reproductive tract of Aplysia. Brain Res Mol Brain Res 2001, 91:163-168.
50. Charlab R., Valenzuela J.G., Andersen J., Ribeiro J.M. The invertebrate growth factor/CECR1 subfamily of adenosine deaminase proteins. Gene 2001, 267:13-22.
51. Homma K.J., Tanaka Y., Matsushita T., Yokoyama K., Matsui H., Natori S. Adenosine deaminase activity of insect-derived growth factor is essential for its growth factor activity. J Biol Chem 2001, 276:43761-43766.
52. Riazi M.A., Brinkman-Mills P., Nguyen T., Pan H., Phan S., Ying F., et al. The human homolog of insect-derived growth factor, CECR1, is a candidate gene for features of cat eye syndrome. Genomics 2000, 64:277-285.
53. Riazi A.M., Van Arsdell G., Buchwald M. Transgenic expression of CECR1 adenosine deaminase in mice results in abnormal development of heart and kidney. Transgenic Res 2005, 14:333-336.
54. Ajees A.A., Anantharamaiah G.M., Mishra V.K., Hussain M.M., Murthy H.M. Crystal structure of human apolipoprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci U S A 2006, 103:2126-2131.
55. Ortiz C., Meneses R., Jaffe D., Fernandez J.A., Perez G., Bourgoignie J.J. Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 1988, 34:248-253.
56. Sezer S., Tutal E., Arat Z., Akcay A., Celik H., Ozdemir F.N., et al. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients. J Ren Nutr 2005, 15:427-434.
57. Sainz I.M., Pixley R.A., Colman R.W. Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology. Thromb Haemost 2007, 98:77-83.
58. Guo Y.L., Colman R.W. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J Thromb Haemost 2005, 3:670-676.
59. Colman R.W., Pixley R.A., Sainz I.M., Song J.S., Isordia-Salas I., Muhamed S.N., et al. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J Thromb Haemost 2003, 1:164-170.
60. Hayashi I., Amano H., Yoshida S., Kamata K., Kamata M., Inukai M., et al. Suppressed angiogenesis in kininogen-deficiencies. Lab Invest 2002, 82:871-880.
61. Isordia-Salas I., Pixley R.A., Li F., Sainz I., Sartor R.B., Adam A., et al. Kininogen deficiency modulates chronic intestinal inflammation in genetically susceptible rats. Am J Physiol Gastrointest Liver Physiol 2002, 283:G180-G186.
62. Bongcam-Rudloff E., Nister M., Betsholtz C., Wang J.L., Stenman G., Huebner K., et al. Human glial fibrillary acidic protein: complementary DNA cloning, chromosome localization, and messenger RNA expression in human glioma cell lines of various phenotypes. Cancer Res 1991, 51:1553-1560.
63. Basile D.P. The transforming growth factor beta system in kidney disease and repair: recent progress and future directions. Curr Opin Nephrol Hypertens 1999, 8:21-30.
64. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
65. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993, 327:125-130.
66. Roberts A.B., McCune B.K., Sporn M.B. TGF-beta: regulation of extracellular matrix. Kidney Int 1992, 41:557-559.
67. Yokoi H., Mukoyama M., Sugawara A., Mori K., Nagae T., Makino H., et al. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 2002, 282:F933-F942.